Clinical TrialApr 22, 2026, 07:02 AM
Kyverna Reports Positive Phase 2/3 Data for miv-cel in gMG & SPS
AI Summary
Kyverna Therapeutics announced positive clinical trial results for its drug miv-cel. On April 20, 2026, the company reported positive longer-term follow-up data from the Phase 2 portion of its KYSA-6 trial for miv-cel in generalized myasthenia gravis. The following day, April 21, 2026, Kyverna released positive primary analysis results from its KYSA-8 registrational trial of miv-cel in stiff person syndrome. The company hosted a conference call on April 22, 2026, to discuss these findings.
Key Highlights
- Kyverna announced positive longer-term follow-up data from Phase 2 of KYSA-6 trial.
- Miv-cel showed positive results in generalized myasthenia gravis (gMG).
- Company reported positive primary analysis results from KYSA-8 registrational trial.
- Miv-cel demonstrated positive outcomes in stiff person syndrome (SPS).
- A conference call was scheduled for April 22, 2026, to review the results.
Price Impact
More from KYTX